Immunogenicity of Intradermal Versus Intramuscular BNT162b2 COVID-19 Booster Vaccine in Patients with Immune-Mediated Dermatologic Diseases: A Non-Inferiority Randomized Controlled Trial DOI Creative Commons
Chutima Seree-aphinan, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(1), P. 73 - 73

Published: Jan. 11, 2024

The intradermal route has emerged as a dose-sparing alternative during the coronavirus disease 2019 (COVID-19) pandemic. Despite its efficacy in healthy populations, immunogenicity not been tested immune-mediated dermatologic (IMDD) patients. This assessor-blinded, randomized-controlled, non-inferiority trial recruited patients with two representative IMDDs (i.e., psoriasis and autoimmune bullous diseases) to vaccinate fractionated-dose (fID) or standard intramuscular (sIM) BNT162b2 vaccines fourth booster dose under block randomization stratified by age, sex, their skin diseases. Post-vaccination SARS-CoV-2-specific IgG interferon-γ responses measured 4 12 weeks post-intervention were serological surrogates used for demonstrating treatment effects. Mean differences log-normalized outcome estimates calculated multivariable linear regression adjusting baseline values, systemic immunosuppressants used, prior COVID-19 vaccination history. margin was set fID retain >80% of sIM. With 109 participants included, 53 received (all entered an intention-to-treat analysis). demonstrated sIM humoral (mean sIM: 3.3, ΔfID-sIM [mean, 95%CI]: -0.1, -0.3 0.0) cellular 3.2, 0.1, -0.2 0.3) outcomes. Two from arm (3.8%) developed injection-site Koebner's phenomenon. Fewer recipients experienced post-vaccination fever (fID vs. 1.9% 12.5%,

Language: Английский

Opportunities and challenges for T cell-based influenza vaccines DOI
Tim R. Mosmann, Andrew J. McMichael,

Alexandre LeVert

et al.

Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(10), P. 736 - 752

Published: May 2, 2024

Language: Английский

Citations

21
Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme DOI
Tanvir Ahmed,

Kazi Tasnuva Alam

AAPS PharmSciTech, Journal Year: 2025, Volume and Issue: 26(3)

Published: Feb. 21, 2025

Language: Английский

Citations

1
In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD DOI Creative Commons
Juan Shi, Yuejie Zhu,

Zhengwei Yin

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 27, 2024

Abstract Brucella , a gram-negative intracellular bacterium, causing Brucellosis, zoonotic disease with range of clinical manifestations, from asymptomatic to fever, fatigue, loss appetite, joint and muscle pain, back severe patients have developed serious diseases affecting various organs. The mRNA vaccine is an innovative type that anticipated supplant traditional vaccines. It widely utilized for preventing viral infections tumor immunotherapy. However, research regarding its effectiveness in bacterial limited. In this study, we analyzed the epitopes two proteins brucella TonB-dependent outer membrane receptor BtuB LPS assembly protein LptD, which involved nutrient transport synthesis . order effectively stimulate cellular humoral immunity, utilize immunoinformatics tools such as VaxiJen, AllergenFPv.1.0 SignalP 5.0 design proteins. Finally, five cytotoxic T lymphocyte (CTL) cell epitopes, ten helper (HTL) eight B were selected construct vaccine. Computer simulations are also used verify immune response codon optimization, silico cloning showed can efficiently transcript translate E. coli. secondary structure vaccines tertiary structures peptides predicted then docked TLR-4. stability was confirmed through molecular dynamics simulation. These analyses multi-epitope could potentially target extracellular prevalent provided novel strategies developing

Language: Английский

Citations

8
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems DOI Creative Commons
Zhongyan Wu,

Weilu Sun,

Hailong Qi

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(8), P. 873 - 873

Published: Aug. 1, 2024

mRNA vaccines are leading a medical revolution. technologies utilize the host's own cells as bio-factories to produce proteins that serve antigens. This revolutionary approach circumvents complicated processes involved in traditional vaccine production and empowers with ability respond emerging or mutated infectious diseases rapidly. Additionally, robust cellular immune response elicited by has shown significant promise cancer treatment. However, inherent instability of complexity tumor immunity have limited its broader application. Although emergence pseudouridine ionizable cationic lipid nanoparticles (LNPs) made clinical application possible, there remains substantial potential for further improvement immunogenicity delivered antigens preventive therapeutic effects technology. Here, we review latest advancements vaccines, including but not target selection delivery systems. offers multifaceted perspective on this rapidly evolving field.

Language: Английский

Citations

7
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications DOI Creative Commons
Yingying Shi,

Miaoyuan Shi,

Yì Wáng

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 14, 2024

Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.

Language: Английский

Citations

7
Advances in Vaccine Development for Chlamydia trachomatis DOI Creative Commons
Taylor B. Poston

Pathogens and Disease, Journal Year: 2024, Volume and Issue: 82

Published: Jan. 1, 2024

Abstract Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection globally. Antibiotic treatment highly effective, but often asymptomatic resulting in individuals going undetected and untreated. This untreated can ascend to upper female genital tract cause pelvic inflammatory disease, tubal factor infertility, ectopic pregnancy. screening programs have failed control this epidemic demonstrate need for an efficacious vaccine prevent transmission disease. Animal models human epidemiological data reveal that natural immunity provide partial or short-lived sterilizing immunity. These further importance of eliciting interferon gamma (IFNγ)-producing cluster differentiation 4 (CD4) T cells (Th1 Th1/17 cells) likely synergize with antibody-mediated opsonophagocytosis optimal protection. studies guided preclinical rational design decades first Phase 1 clinical trials recently been completed. Recent advances led improvements platforms clinically safe adjuvants help a path forward. review describes models, correlates immunity, antigen adjuvant selection, future testing development.

Language: Английский

Citations

6
mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer DOI Creative Commons
Rama Rao Malla, Mundla Srilatha, Batoul Farran

et al.

Molecular Therapy, Journal Year: 2023, Volume and Issue: 32(1), P. 13 - 31

Published: Nov. 3, 2023

Language: Английский

Citations

15
Emerging advances in delivery systems for mRNA cancer vaccines DOI

Zhimei Jiang,

Yanhua Xu, Guangsheng Du

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 287 - 301

Published: May 1, 2024

Language: Английский

Citations

5
mRNA-based vaccines – global approach, challenges, and could be a promising wayout for future pandemics DOI
Shivani Makhijani,

Gehan M. Elossaily,

Satish Rojekar

et al.

Pharmaceutical Development and Technology, Journal Year: 2024, Volume and Issue: 29(6), P. 559 - 565

Published: May 30, 2024

mRNA-based vaccines are assured to significantly boost biopharmaceuticals since outbreak of coronavirus disease- 2019. Respiratory infections, such as influenza, SARS, MERS, COVID-19, and respiratory syncytial virus, often have high transmission rates due their airborne spread. infections can lead severe illness death. These outbreaks cause substantial economic social disruption, seen with the COVID-19 pandemic. In our interconnected world, diseases spread rapidly across borders. (e.g., mRNA-1283) reduce by creating immunity in population, thus lowering incidence these diseases. Vaccines crucial for global health security, helping prevent local from becoming pandemics. Nevertheless, various concerns remain intracellular delivery, susceptibility degradation catalytic hydrolysis, instability several physiological conditions. Therefore, an hour needed address challenges opportunities attaining high-quality stable novel drug delivery systems. The authors contributed extensive review clinical development, progress stability mitigate market needs. addition, discuss advances growth date; which dominate scope therapeutic implementation. Finally, recent trials, adjuvant benefits, prospects discussed.

Language: Английский

Citations

5
mRNA-based HIV-1 vaccines DOI

Shamim Ahmed,

Alon Herschhorn

Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: 37(3)

Published: July 17, 2024

SUMMARY The success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities develop RNA fight other infectious agents. HIV-1 is a lentivirus that integrates into host cell genome and persists for lifetime infected cells. Multiple mechanisms immune evasion have posed significant obstacles development an effective vaccine over last four decades since identification HIV-1. Recently, attempts address some these challenges led multiple studies manufactured, optimized, tested, in different animal models, mRNA-based vaccines. Several clinical trials also been initiated or are planned start soon. Here, we review current strategies applied vaccines, discuss targeting approaches, summarize latest findings, offer insights future

Language: Английский

Citations

5